Copyright
©The Author(s) 2019.
World J Clin Oncol. Feb 24, 2019; 10(2): 75-85
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.75
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.75
Table 1 Patients characteristics n (%)
Characteristic | Folfiri 3 (n = 18) | Bevacizumab folfiri 3 (n = 99) | Aflibercept folfiri 3 (n = 36) | All (n = 153) | Comparison betweentreatments test P-value |
Median age, yr (range) | 62.5 (44-83) | 64 (38-86) | 66 (33-83) | 64 (33-86) | 0.33 |
Gender | |||||
Male | 14 (67) | 50 (51) | 22 (61) | 84 (55) | 0.31 |
Female | 6 (33) | 49 (49) | 14 (39) | 69 (45) | |
Who performance status | |||||
0 | 2 (11) | 12 (12) | 6 (17) | 20 (13) | 0.47 |
1 | 11 (61) | 75 (76) | 25 (69) | 111 (73) | |
2 | 5 (28) | 12 (12) | 5 (14) | 22 (14) | |
Primary location | |||||
Right colon | 3 (17) | 33 (33) | 8 (22) | 44 (29) | 0.51 |
Left colon | 9 (50) | 38 (39) | 15 (42) | 62 (41) | |
Rectum | 6 (33) | 28 (28) | 13 (36) | 47 (30) | |
Initial cancer status | |||||
Synchronous | 14 (88) | 26 (26) | 20 (56) | 46 (30) | 0.09 |
Metachronous | 4 (22) | 73 (74) | 16 (44) | 107 (70) | |
Number of metastases | |||||
0 and 1 | 6 (33) | 29 (29) | 9 (25) | 44 (29) | 0.40 |
2 | 8 (40) | 45 (46) | 12 (33) | 65 (42) | |
3 and more | 4 (22) | 25 (25) | 15 (42) | 44 (29) | |
Surgery of primary | |||||
No | 7 (39) | 38 (38) | 14 (39) | 59 (39) | 1.00 |
Yes | 11 (61) | 61 (62) | 22 (61) | 94 (61) | |
Surgery of metastases | |||||
No | 14 (78) | 78 (79) | 28 (88) | 120 (81) | 0.53 |
Yes | 4 (22) | 21 (21) | 4 (12) | 29 (19) | |
Unknown | - | - | 4 | 4 | |
Line of therapy | |||||
Second | 5 (28) | 17 (17) | 4 (12) | 26 (17) | 0.52 |
Third | 3 (17) | 22 (22) | 11 (31) | 36 (24) | |
More | 10 (55) | 60 (61) | 21 (57) | 91 (59) | |
Irinotecan chemotherapy-naive | |||||
No | 13 (72) | 81 (82) | 31 (86) | 125 (82) | 0.46 |
Yes | 5 (28) | 18 (18) | 5 (14) | 28 (18) | |
RAS/BRAF mutation status | |||||
Not mutated | 11 (69) | 36 (44) | 16 (44) | 63 (47) | 0.18 |
At least one mutated | 5 (31) | 46 (56) | 20 (56) | 71 (53) | |
Unknown | 2 | 17 | - | 19 | |
Best overall response | |||||
PD | 3 (17) | 8 (8) | 0 (0) | 11 (7) | 0.20 |
SD | 1 (5) | 9 (9) | 7 (19) | 17 (11) | |
PR | 11 (61) | 48 (48.5) | 15 (42) | 74 (48) | |
CR | 0 (0) | 3 (3) | 1 (3) | 4 (3) | |
NE | 3 (17) | 31 (31.5) | 13 (36) | 47 (31) | |
Median PFS, mo (95%CI) | 3.0 (0.8-6.9) | 3.7 (3.0-5.3) | 4.7 (3.3-12.8) | 3.9 (3.2-4.9) | - |
Median OS, mo (95%CI) | 5.6 (4.0-20.2) | 8.5 (6.4-10.7) | 13.7 (7.9-18.7) | 9.4 (6.6-12.0) | - |
Table 2 Summary of chemotherapy toxicity n (%)
Characteristic | Folfiri 3 (n = 18) | Bevacizumab folfiri 3 (n = 99) | Aflibercept folfiri 3 (n = 36) | All (n = 153) |
Anemia | ||||
No | 14 | 79 | 29 | 122 |
Grade 1 | 2 | 10 | 5 | 17 |
Grade 2 | 0 | 8 | 0 | 8 |
Grade 3 | 2 | 1 | 2 | 5 |
Grade 4 | 0 | 1 | 0 | 1 |
Thrombopenia | ||||
No | 17 | 91 | 31 | 139 |
Grade 1 | 0 | 5 | 3 | 8 |
Grade 2 | 0 | 2 | 0 | 2 |
Grade 3 | 1 | 0 | 0 | 1 |
Grade 4 | 0 | 1 | 2 | 3 |
Neutropenia | ||||
No | 13 | 87 | 26 | 126 |
Grade 1 | 1 | 0 | 1 | 2 |
Grade 2 | 2 | 1 | 4 | 7 |
Grade 3 | 1 | 9 | 4 | 14 |
Grade 4 | 1 | 2 | 1 | 4 |
Diarrheoa | ||||
No | 9 | 48 | 11 | 68 |
Grade 1 | 2 | 18 | 8 | 28 |
Grade 2 | 5 | 14 | 5 | 24 |
Grade 3 | 2 | 14 | 11 | 27 |
Grade 4 | 0 | 5 | 1 | 6 |
Stomitis | ||||
No | 13 | 83 | 27 | 123 |
Grade 1 | 2 | 5 | 5 | 12 |
Grade 2 | 2 | 8 | 4 | 14 |
Grade 3 | 0 | 1 | 0 | 1 |
Grade 4 | 1 | 2 | 0 | 3 |
Nausea | ||||
No | 17 | 81 | 28 | 126 |
Grade 1 | 1 | 8 | 5 | 14 |
Grade 2 | 0 | 10 | 3 | 13 |
Vomiting | ||||
No | 17 | 90 | 31 | 138 |
Grade 1 | 0 | 3 | 4 | 7 |
Grade 2 | 0 | 3 | 1 | 4 |
Grade 3 | 1 | 3 | 0 | 4 |
Hyperblood pressure | ||||
No | 18 | 98 | 36 | 152 |
Yes | 0 | 1 | 0 | 1 |
Bleeding | ||||
No | 17 | 95 | 30 | 142 |
Yes | 1 | 4 | 6 | 11 |
Venous thrombosis | ||||
No | 18 | 97 | 36 | 151 |
Yes | 0 | 2 | 0 | 2 |
Digestive perforation | ||||
No | 18 | 98 | 36 | 152 |
Yes | 0 | 1 | 0 | 1 |
Table 3 Results of Cox univariate analyses
Characteristic | Progression-free survival | Overall survival | ||||
Hazard ratio | 95%CI | P-value | Hazard ratio | 95%CI | P-value | |
Age, yr | ||||||
Continuous | 0.999 | 0.984; 1.016 | 0.98 | 1.002 | 0.986; 1.018 | 0.81 |
Gender | ||||||
Female | 1 | 1 | ||||
Male | 0.827 | 0.597; 1.145 | 0.25 | 0.898 | 0.645; 1.251 | 0.53 |
Who performance status | ||||||
0 | 1 | 1 | ||||
1 | 1.569 | 0.926; 2.660 | 0.09 | 2.039 | 0.143; 3.639 | 0.02 |
2 | 2.827 | 0.473; 5.428 | 0.002 | 5.335 | 2.647; 10.75 | < 0.01 |
Primary location | ||||||
Right colon | 1 | 1 | ||||
Left colon | 0.979 | 0.660; 1.454 | 0.92 | 0.945 | 0.634; 1.410 | 0.78 |
Rectum | 1.018 | 0.671; 1.545 | 0.93 | 1.029 | 0.673; 1.572 | 0.90 |
Initial cancer status | ||||||
Synchronous | 1 | 1 | ||||
Metachronous | 0.815 | 0.572; 1.162 | 0.26 | 0.839 | 0.583; 1.208 | 0.34 |
No. of metastastatic sites | ||||||
1 | 1 | 1 | ||||
2 | 1.225 | 0.823; 1.823 | 0.32 | 1.241 | 0.824; 1.870 | 0.30 |
≥ 3 | 1.361 | 0.883; 2.098 | 0.16 | 1.490 | 0.954; 2.326 | 0.08 |
Surgery of primary | ||||||
No | 1 | 1 | ||||
Yes | 0.789 | 0.564; 1.104 | 0.17 | 0.799 | 0.568; 1.124 | 0.20 |
Surgery of metastases | ||||||
No | 1 | 1 | ||||
Yes | 0.592 | 0.388; 0.903 | 0.01 | 0.725 | 0.475; 1.107 | 0.13 |
Line of therapy | ||||||
Second | 1 | 1 | ||||
Third | 1.055 | 0.615; 1.812 | 0.85 | 1.126 | 0.646; 1.962 | 0.68 |
More | 1.728 | 1.060; 2.816 | 0.03 | 1.531 | 0.931; 2.517 | 0.09 |
Treatment | ||||||
FOLFIRI | 1 | 1 | ||||
FOLFIRI3 + Bevacizumab | 1.055 | 0.615; 1.812 | 0.85 | 0.791 | 0.471; 1.329 | 0.38 |
FOLFIRI3 + Aflibercept | 1.728 | 1.060; 2.816 | 0.03 | 0.470 | 0.255; 0.866 | 0.02 |
Irinotecan chemotherapy-naive | ||||||
1 | 1 | |||||
No vs yes | 0.731 | 0.474; 1.127 | 0.15 | 0.838 | 0.539; 1.303 | 0.43 |
RAS/BRAF mutation status | ||||||
Not mutated | 1 | 1 | ||||
Mutated | 0.910 | 0.641; 1.293 | 0.60 | 0.986 | 0.690; 1.408 | 0.94 |
Table 4 Results of Cox univariate analyses
Characteristic | Progression-free survival | Overall survival | ||||
Hazard ratio | 95%CI | P-value | Hazard ratio | 95%CI | P-value | |
Age, yr | ||||||
Continuous | 0.990 | 0.968; 1.012 | 0.36 | 0.988 | 0.968; 1.007 | 0.22 |
Gender | ||||||
Female | 1 | 1 | ||||
Male | 1.003 | 0.673; 1.497 | 0.99 | 0.992 | 0.655; 1.502 | 0.97 |
Who performance status | ||||||
0 | 1 | 1 | ||||
1 | 1.588 | 0.832; 3.034 | 0.16 | 2.157 | 1.086; 4.284 | 0.03 |
2 | 2.165 | 0.925; 5.068 | 0.08 | 4.865 | 2.061; 11.49 | < 0.001 |
Primary location | ||||||
Right colon | 1 | 1 | ||||
Left colon | 0.953 | 0.589; 1.541 | 0.84 | 0.919 | 0.556; 1.520 | 0.74 |
Rectum | 1.054 | 0.634; 1.752 | 0.84 | 0.879 | 0.525; 1.470 | 0.62 |
Initial cancer status | ||||||
Synchronous | 1 | 1 | ||||
Metachronous | 0.862 | 0.554; 1.340 | 0.51 | 0.887 | 0.562; 1.398 | 0.60 |
Number of metastastatic sites | ||||||
1 | 1 | 1 | ||||
2 | 1.040 | 0.640; 1.692 | 0.87 | 1.085 | 0.654; 1.798 | 0.75 |
≥ 3 | 1.347 | 0.796; 2.279 | 0.27 | 1.449 | 0.847; 2.476 | 0.18 |
Surgery of primary | ||||||
No | 1 | 1 | ||||
Yes | 0.947 | 0.622; 1.442 | 0.80 | 0.893 | 0.575; 1.387 | 0.61 |
Surgery of metastases | ||||||
No | 1 | 1 | ||||
Yes | 0.562 | 0.342; 0.924 | 0.02 | 0.754 | 0.458; 1.241 | 0.27 |
Line of therapy | ||||||
Second | 1 | 1 | ||||
Third | 0.878 | 0.421; 1.832 | 0.73 | 0.944 | 0.441; 2.020 | 0.88 |
More | 1.340 | 0.655; 2.740 | 0.42 | 1.155 | 0.548; 2.432 | 0.71 |
Treatment | ||||||
FOLFIRI3 | 1 | 1 | ||||
FOLFIRI3 + Bevacizumab | 0.547 | 0.304; 0.983 | 0.04 | 0.647 | 0.354; 1.180 | 0.16 |
FOLFIRI3 + Aflibercept | 0.354 | 0.181; 0.694 | 0.002 | 0.367 | 0.184; 0.729 | 0.004 |
Irinotecan chemotherapy-naive | ||||||
No | 1 | 1 | ||||
Yes | 0.979 | 0.548; 1.748 | 0.94 | 1.114 | 0.609; 2.038 | 0.73 |
RAS/BRAF mutation status | ||||||
Not mutated | 1 | 1 | ||||
Mutated | 1.045 | 0.679; 1.611 | 0.84 | 1.232 | 0.784; 1.935 | 0.37 |
- Citation: Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85
- URL: https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i2.75